급성 관상동맥 증후군 시장 : 시장 예측(2026-2032년)

The Acute Coronary Syndrome Market is projected to grow by USD 13.57 billion at a CAGR of 6.85% by 2032.

Acute Coronary Syndrome Executive Summary

Acute coronary syndrome (ACS) remains one of the most urgent cardiovascular conditions, encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. It is driven by reduced coronary blood flow, most often from plaque rupture and thrombosis, and requires rapid diagnosis, risk stratification, reperfusion when indicated, antithrombotic therapy, lipid management, and long-term secondary prevention. The clinical and economic burden is reinforced by aging populations, persistent hypertension, diabetes, obesity, tobacco exposure, chronic kidney disease, physical inactivity, and gaps in access to timely emergency cardiac care. Current ACS care is shaped by guideline-directed pathways that emphasize high-sensitivity cardiac troponin testing, electrocardiogram-based triage, early invasive assessment for high-risk patients, percutaneous coronary intervention, dual antiplatelet therapy, statins, beta-blockers, renin-angiotensin system inhibitors where appropriate, cardiac rehabilitation, and lifestyle modification. The themes in the acute coronary syndrome landscape include myocardial infarction diagnosis, chest pain management, emergency cardiology, coronary artery disease treatment, antiplatelet therapy, high-sensitivity troponin, PCI care pathways, and secondary cardiovascular prevention. Stakeholders across hospitals, payers, policymakers, device developers, diagnostics providers, and pharmaceutical innovators are increasingly focused on shortening door-to-balloon and door-to-needle times, improving adherence to evidence-based therapies, expanding catheterization capacity, and reducing recurrent cardiovascular events after discharge.

Transformative Shifts in the Acute Coronary Syndrome Landscape

The ACS landscape is undergoing a measurable shift from reactive emergency treatment toward integrated, time-sensitive, data-enabled cardiovascular care. Emergency medical services and chest pain networks are prioritizing pre-hospital electrocardiogram transmission, direct transfer to PCI-capable centers, standardized triage protocols, and regional hub-and-spoke models to improve reperfusion timelines. Diagnostic practice has also changed significantly with the adoption of high-sensitivity troponin assays, which enable earlier rule-in and rule-out algorithms for myocardial infarction and reduce unnecessary admissions when paired with clinical risk scores. Treatment pathways are increasingly individualized according to ischemic risk, bleeding risk, frailty, renal function, age, prior stroke, and the likelihood of medication adherence. The role of radial access PCI, potent P2Y12 inhibitors, anticoagulation optimization, intravascular imaging, and complete revascularization strategies continues to influence procedural decision-making. At the same time, health systems are placing greater emphasis on post-ACS continuity of care, including cardiac rehabilitation enrollment, smoking cessation, blood pressure control, diabetes management, LDL-cholesterol reduction, and structured follow-up to prevent readmissions. The transformation is also visible in patient engagement, with remote monitoring, digital adherence tools, telecardiology, and home-based rehabilitation supporting recovery beyond the hospital setting.

Cumulative Impact of Artificial Intelligence in ACS Care

Artificial intelligence is becoming increasingly relevant across the ACS care continuum, particularly in early detection, triage, clinical decision support, imaging interpretation, operational efficiency, and post-discharge risk management. In emergency settings, AI-enabled electrocardiogram analysis can support faster recognition of acute myocardial infarction patterns and identify subtle ischemic signals that may be missed during high-volume triage. Machine learning models are also being evaluated to combine symptoms, vital signs, electrocardiographic findings, laboratory results, and comorbidity profiles to support risk stratification for chest pain patients. In diagnostics, AI may enhance echocardiography, coronary CT angiography, and invasive imaging workflows by assisting with wall motion assessment, plaque characterization, coronary stenosis evaluation, and procedural planning. For hospital operations, predictive analytics can help anticipate catheterization laboratory demand, emergency department crowding, and readmission risk. In secondary prevention, AI-driven tools may identify patients at higher risk of medication nonadherence, recurrent events, or missed follow-up, enabling more targeted interventions. However, responsible use requires validation across diverse populations, transparent model performance, clinician oversight, cybersecurity safeguards, bias monitoring, and alignment with regulatory expectations. The cumulative impact of AI in ACS is therefore strongest when technology supports, rather than replaces, clinician judgment, guideline-based care, and equitable access to timely cardiovascular treatment.

Key Regional Insights: Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

In Asia-Pacific, ACS trends are shaped by rapid urbanization, high tobacco exposure in several countries, rising diabetes prevalence, air pollution exposure, and expanding hospital infrastructure, with major emphasis on improving emergency response systems, PCI access, chest pain center certification, and prevention programs. Europe benefits from well-established cardiology guidelines, extensive acute cardiac care networks, and strong adoption of radial PCI and cardiac rehabilitation, while national variations remain in timely access, workforce capacity, rehabilitation participation, and post-discharge adherence. North America demonstrates advanced uptake of high-sensitivity troponin testing, mature catheterization networks, broad use of evidence-based secondary prevention, and strong focus on quality metrics such as door-to-balloon time, though disparities persist across rural communities, uninsured or underinsured populations, and Indigenous groups. Latin America faces a dual challenge of rising cardiometabolic risk and uneven access to specialized cardiac centers, making regionalized STEMI networks, affordable antiplatelet therapy, thrombolysis availability, and public health prevention particularly important. Africa faces substantial constraints in emergency transport, catheterization laboratory availability, troponin testing access, specialist workforce, and affordability of long-term therapy, making scalable diagnosis, prevention, and essential medicine access central priorities. The Middle East is experiencing a high burden of diabetes, obesity, and premature coronary artery disease in several countries, driving demand for advanced cardiac care, prevention strategies, and integrated chronic disease management. Across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East, the most consistent evidence-backed priorities are faster diagnosis, guideline-concordant reperfusion, bleeding-aware antithrombotic strategies, cardiac rehabilitation, lipid lowering, and long-term risk factor modification.

Key Group Insights: NATO, G7, BRICS, European Union, ASEAN, and GCC

Across NATO countries, ACS readiness is supported in many members by advanced emergency systems, catheterization infrastructure, and evidence-based cardiology pathways, while differences in rural access, workforce capacity, and supply chain resilience make emergency preparedness and continuity of essential cardiovascular medicines relevant to ACS response. The G7 group generally demonstrates strong availability of advanced diagnostics, PCI infrastructure, pharmacotherapy, rehabilitation programs, and digital health capabilities, with ongoing policy attention to aging populations, healthcare workforce pressure, chronic disease prevention, and equity in rural or socioeconomically disadvantaged areas. BRICS countries show highly diverse ACS readiness, ranging from advanced metropolitan cardiac centers to resource-limited settings where delays in presentation, diagnostic access, emergency transport, and affordability of long-term medicines remain critical barriers. The European Union benefits from harmonized clinical guidance, structured quality improvement, and cross-country emphasis on timely reperfusion, high-sensitivity troponin use, radial access PCI, and secondary prevention, though differences in reimbursement, rural access, and rehabilitation participation still affect outcomes. Among ASEAN countries, ACS care is influenced by a growing burden of diabetes, hypertension, smoking-related cardiovascular disease, and variable access to PCI-capable hospitals, encouraging investment in STEMI networks, ambulance coordination, chest pain pathways, and affordable diagnostics. In the GCC, high rates of obesity, diabetes, and sedentary lifestyle patterns have made premature coronary disease a priority, while relatively advanced tertiary care capacity supports adoption of catheter-based interventions, high-sensitivity biomarkers, and integrated preventive cardiology. These group-level patterns show that ACS performance depends not only on clinical technology but also on coordinated emergency systems, reimbursement design, public health prevention, essential medicine access, and adherence-focused long-term care.

Key Country Insights Across Major Acute Coronary Syndrome Markets

China is expanding chest pain centers, PCI capacity, emergency coordination, and national quality initiatives, while urban-rural differences, smoking exposure, hypertension, and high cardiometabolic risk remain central concerns. The United States has a highly developed ACS treatment ecosystem with broad PCI availability, high-sensitivity troponin adoption, advanced emergency cardiac protocols, and strong secondary prevention guidance, although rural access, insurance status, and racial disparities continue to influence timely care. Japan has advanced cardiovascular infrastructure, high-quality acute care, and an aging population that increases complexity related to frailty, bleeding risk, renal impairment, and polypharmacy. India faces a large burden of premature coronary artery disease, diabetes, hypertension, and tobacco exposure, making early recognition, affordability, emergency transport, and access to PCI or thrombolysis key priorities. Germany has extensive hospital and catheterization capacity, strong guideline uptake, and advanced cardiovascular services, while prevention, rehabilitation participation, and care coordination remain important priorities. The United Kingdom relies on structured national pathways for chest pain, myocardial infarction care, PCI, and rehabilitation, with system pressure and waiting times influencing follow-up care. Australia benefits from mature ACS guidelines, strong emergency care systems, and telehealth use for remote regions, though geographic distance remains a barrier for timely intervention. France combines comprehensive coverage with organized emergency and cardiology services, supporting timely ACS care in many regions and emphasizing secondary prevention after discharge. South Korea demonstrates advanced hospital infrastructure, high procedural capability, and increasing emphasis on prevention, rapid triage, and post-ACS management. Italy and Spain have established cardiology networks and PCI expertise, with ongoing focus on aging populations, rehabilitation, medication adherence, and recurrent event prevention. Canada emphasizes regional STEMI systems, evidence-based pharmacotherapy, and universal coverage, while geography and remote community access remain operational challenges. Russia faces a substantial cardiovascular disease burden, with ACS outcomes shaped by access to reperfusion, risk factor prevalence, emergency response variation, and regional service differences. Brazil has major urban cardiac centers and public health initiatives, but regional inequality affects ACS diagnosis, catheterization access, rehabilitation, and medicine continuity. Mexico continues to strengthen emergency cardiovascular pathways, with opportunities centered on faster diagnosis, broader reperfusion access, risk factor control, and continuity of care. Across these countries, ACS outcomes are most strongly influenced by speed of presentation, availability of reperfusion, diagnostic reliability, adherence to antithrombotic and lipid-lowering therapy, and continuity of secondary prevention.

Actionable Recommendations for Acute Coronary Syndrome Industry Leaders

Industry leaders should prioritize solutions that reduce time to diagnosis, support guideline-concordant decision-making, and improve long-term outcomes after ACS discharge. Hospitals and care networks should strengthen pre-hospital ECG transmission, direct activation of catheterization laboratories, regional STEMI coordination, high-sensitivity troponin algorithms, and standardized chest pain pathways. Diagnostic and technology developers should focus on clinically validated tools that integrate seamlessly into emergency workflows, reduce false positives and false negatives, and demonstrate performance across age, sex, ethnicity, and comorbidity groups. Pharmaceutical and device stakeholders should align innovation with bleeding-risk personalization, medication adherence, real-world evidence generation, and access in underserved settings. Payers and policymakers should support cardiac rehabilitation, essential cardiovascular medicines, smoking cessation, hypertension control, diabetes care, lipid management, and rural emergency transport as core components of ACS prevention and recovery. Digital health leaders should develop interoperable platforms for remote monitoring, discharge planning, medication reminders, rehabilitation engagement, and risk-based follow-up. Across all stakeholder groups, the highest-value actions are those that improve speed, equity, affordability, clinical quality, and measurable patient outcomes without creating additional workflow burden for emergency and cardiology teams.

Research Methodology

This executive summary is built on an evidence-based research methodology that synthesizes verified clinical, epidemiological, regulatory, and healthcare delivery information from authoritative public health sources, peer-reviewed literature, clinical practice guidelines, hospital care standards, and cardiovascular quality frameworks. The methodology emphasizes triangulation across multiple credible evidence streams, including guideline recommendations for ACS diagnosis and treatment, published data on cardiovascular risk factors, documented care pathway practices, and regional health system characteristics. Insights were evaluated for clinical relevance, consistency, recency, and applicability across emergency care, interventional cardiology, diagnostics, pharmacotherapy, rehabilitation, and secondary prevention. Regional, group, and country analyses were developed using documented differences in disease burden, healthcare infrastructure, emergency transport, catheterization capacity, access to medicines, and prevention programs. Artificial intelligence insights were assessed through the lens of clinical validation, workflow integration, algorithmic bias, data governance, and regulatory readiness. The analysis intentionally excludes market sizing, market share, revenue estimates, and forecasts, focusing instead on verified trends, care delivery dynamics, clinical adoption factors, and actionable strategic implications for stakeholders in the acute coronary syndrome ecosystem.

Conclusion

Acute coronary syndrome remains a critical global cardiovascular priority because outcomes depend on rapid recognition, timely reperfusion, evidence-based pharmacotherapy, and sustained secondary prevention. The landscape is moving toward integrated chest pain systems, high-sensitivity diagnostics, individualized antithrombotic strategies, digitally supported follow-up, and AI-enabled decision support. Regional, group, and country-level differences show that advanced technology alone is insufficient without reliable emergency transport, trained clinical teams, affordable medicines, rehabilitation access, and prevention of cardiometabolic risk factors. For industry leaders, the most important opportunities lie in improving diagnostic speed, expanding equitable access to reperfusion, strengthening adherence after discharge, supporting cardiac rehabilitation, and validating digital and AI tools in real-world clinical settings. The future of ACS care will be defined by systems that combine precision, speed, safety, and continuity, delivering better outcomes for patients while reducing preventable recurrent cardiovascular events.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Acute Coronary Syndrome Market, by Diagnosis Type

• 7.1. Introduction
• 7.2. Electrocardiography (ECG)
  • 7.2.1. Resting ECG
  • 7.2.2. Continuous ECG Monitoring
• 7.3. Biomarker Testing
  • 7.3.1. Troponin Testing
  • 7.3.2. CK-MB Testing
  • 7.3.3. Myoglobin Testing
• 7.4. Imaging Diagnostics
  • 7.4.1. Echocardiography
  • 7.4.2. Coronary Angiography
  • 7.4.3. CT Coronary Angiography
• 7.5. Stress Testing

8. Acute Coronary Syndrome Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Oral Administration
• 8.3. Intravenous Administration
• 8.4. Subcutaneous Administration

9. Acute Coronary Syndrome Market, by Treatment Type

• 9.1. Introduction
• 9.2. Pharmacological Treatment
• 9.3. Interventional Treatment

10. Acute Coronary Syndrome Market, by End User

• 10.1. Introduction
• 10.2. Home Healthcare Providers
• 10.3. Hospitals
• 10.4. Research & Academic Institutes
• 10.5. Specialty Clinics

11. Acute Coronary Syndrome Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Online
• 11.3. Offline

12. Acute Coronary Syndrome Market, by Drug Class

• 12.1. Introduction
• 12.2. Antiplatelet Agents
• 12.3. Anticoagulants
• 12.4. Thrombolytics
• 12.5. Beta Blockers
• 12.6. ACE Inhibitors
• 12.7. Angiotensin Receptor Blockers (ARBs)
• 12.8. Statins
• 12.9. Vasodilators

13. Acute Coronary Syndrome Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Acute Coronary Syndrome Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Acute Coronary Syndrome Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Amgen Inc.
• 17.3. AstraZeneca PLC
• 17.4. Baxter International, Inc.
• 17.5. Bayer AG
• 17.6. bioMerieux SA
• 17.7. Biosensors International Group, Ltd.
• 17.8. Boehringer Ingelheim International GmbH
• 17.9. Boston Scientific Corporation
• 17.10. DAIICHI SANKYO COMPANY, LIMITED
• 17.11. Dalcor Pharmaceuticals
• 17.12. Dr. Reddy's Laboratories Ltd.
• 17.13. Eli Lilly and Company
• 17.14. F. Hoffmann-La Roche Ltd.
• 17.15. GlaxoSmithKline plc
• 17.16. Koninklijke Philips N.V.
• 17.17. Medtronic PLC
• 17.18. Merck & Co, Inc.
• 17.19. Novartis AG
• 17.20. Pfizer Inc.
• 17.21. Regeneron Pharmaceuticals Inc.
• 17.22. Sanofi S.A.
• 17.23. Siemens AG
• 17.24. Terumo Corporation
• 17.25. Teva Pharmaceutical Industries Ltd.